Figure 1: Antibodies from AChR-Ab–seronegative MG patients bind to MuSK. Figure 3: MuSK IgG antibodies induce AChR clusters but inhibit agrin-induced clustering. COS7 cells were plated onto ...

Receptor tyrosine kinases (RTKs ... targeted in different types of cancer using tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. Therefore, the inhibitory effects of different TKIs ...

Protein tyrosine ... kinase by interfering with the binding of ATP or substrates. Other anti-TK drugs may inhibit activation of fusion TKs by blocking their dimerization. Antibodies against ...

The locations of tumor-associated mutations, all within the tyrosine kinase domain ... used as a marker of receptor activation, with the use of Western blotting with an antibody that specifically ...

Molecular alterations in NSCLC that drive cancer growth have led to multiple tyrosine kinase inhibitors with distinct pharmacologic ... Although in use across other cancers, antibody-drug conjugates ...

One of the novel pathways under investigation is the inhibition of Bruton tyrosine kinase ... Microglial Fc receptors mediate physiological changes resulting from antibody cross-linking of ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

Tyrosine kinase inhibitors are particularly important agents because these high-affinity cell surface receptors play a critical role in the progression of many cancers. Tyrosine kinases are ...

The IMPROVE study investigated whether a three-week pause in BTKi therapy around the time of COVID-19 vaccination would improve the antibody ... continued Bruton tyrosine kinase inhibitor use ...